EDDING GENOR (06998): First-in-human Phase I clinical study data for GB268 released at the 2026 ESMO Congress
Edding Genor (06998) announced that preliminary data from the first-in-human Phase I clinical study of GB268 have been released in poster form at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No.: 1963P). The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors.
EDDING GENOR (06998) announced that preliminary data from the first-in-human Phase I clinical study of GB268 were released in poster form at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No.: 1963P). The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors.
Related Articles
Shenwan Hongyuan Group: Short-term market cost-effectiveness has significantly improved; oversold rebound small and micro-cap stocks and themes have higher elasticity.
Montage Technology (06809): From the "memory bear market" to CPU shipmentsafter the 9% rebound, the quality of the recovery still awaits Q4 validation.
Performance Rising vs. Share Price Falling: Is It the Right Time for ZIJIN GOLD INTL (02259) Valuation Repair?
Shenwan Hongyuan Group: Short-term market cost-effectiveness has significantly improved; oversold rebound small and micro-cap stocks and themes have higher elasticity.
Montage Technology (06809): From the "memory bear market" to CPU shipmentsafter the 9% rebound, the quality of the recovery still awaits Q4 validation.
Performance Rising vs. Share Price Falling: Is It the Right Time for ZIJIN GOLD INTL (02259) Valuation Repair?
